Molecular Partners Ag (MOLN) Restructuring Costs (2025)
Molecular Partners Ag (MOLN) posted quarterly Restructuring Costs of -$3.4 million for Q4 2025, down 2327102.31% on a QoQ basis from -$145.01 in Q3 2025.
Molecular Partners Ag (MOLN) Restructuring Costs (2025) Analysis & Trends
Molecular Partners Ag (MOLN) has reported Restructuring Costs for 1 consecutive years, with -$3.4 million the latest figure, recorded in Q4 2025.
- Quarterly Restructuring Costs changed N/A year-over-year to -$3.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$3.4 million (changed N/A YoY) and the FY2025 annual result came in at -$3.4 million, changed N/A from the prior year.
- Restructuring Costs eased to -$3.4 million in Q4 2025 per MOLN's latest filing, from -$145.01 in the prior quarter.
- Over the last five years, Restructuring Costs for MOLN reached as high as -$145.01 in Q3 2025 and fell as low as -$3.4 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Molecular Partners Ag | 147.97 Mn | 147.97 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -3.37 Mn |
| Sep 30, 2025 | -145.01 |
| Jun 30, 2025 | -3,161.05 |